A CD34+CD38−CD123+ % >10% was significantly associated with better performance status, secondary AML, poor cytogenetic and ELN 2010 risk, higher albumin levels, and lower ferritin levels as compared to patients with ≤10%. This evidence concerns the gene ALB and acute myeloid leukemia.